Published finding — does the expert body still believe it?
The EMBOLISE trial's stated primary conclusion — MMA embolization as an adjunct to surgical evacuation lowers recurrence for symptomatic chronic subdural hematoma. — replicates in independent cohorts.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 0 snapshots
Registry data
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
A Study of the Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System In the Treatment of Subacute and Chronic Subdural HEmatoma (EMBOLISE)
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0509
The MEMBRANE trial's stated primary conclusion — Middle meningeal artery embolization reduces recurrence of chronic subdural hematoma. — replicates in independent cohorts.
0.1508
By 2028, MMA embolization will be incorporated into AANS/CNS guidelines as a recommended adjunct for recurrent cSDH.
0.1633
Recent follow-up analyses of EMBOLISE are confirming the original effect size in real-world data.
0.1800
By 2028, ≥40% of cSDH evacuations at academic centers will include adjunctive MMA embolization.
0.1948
The ESCAPE trial's stated primary conclusion — Rapid endovascular treatment improves functional outcomes in proximal anterior-circulation stroke. — replicates in independent cohorts.
0.1995
The MR CLEAN trial's stated primary conclusion — Endovascular thrombectomy within 6h improves functional outcome in proximal anterior circulation stroke. — replicates in independent cohorts.